+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Venous Thromboembolism Treatment Market: By Type; By Treatment & By Region - Forecast 2016-2022

  • ID: 4033518
  • Report
  • 147 pages
  • IndustryARC
1 of 2
Venous Thromboembolism (VTE) is a lethal disorder that affects the hospitalized and non-hospitalized patients, recurs frequently, and results in long-term complications including chronic thromboembolic pulmonary hypertension (CTPH) and the post-thrombotic syndrome (PTS). It includes both deep vein thrombosis (DVT) and pulmonary embolism (PE). Globally, development of efficient and advanced technology, rise in the awareness among people regarding existing treatments for venous thromboembolism, increasing government initiatives across the globe, growing prevalence and incidence rate of venous thromboembolism are the prime growth drivers of the venous thromboembolism treatment market. In addition, an increase in adoption of venous thromboembolism treatment in emerging economies such as China, India and others, will create new opportunities for the venous thromboembolism treatment market. However, higher cost of the research and development, and complex government regulatory approvals are the key restraints for the venous thromboembolism treatment market.

Geographically, North America dominated the venous thromboembolism treatment market, because of high medical reimbursement facilities, and technological advancement. Asia Pacific is projected to have the fastest growth, owing to a rapidly increasing population, rise in consumer awareness, favourable government policies, modernization of healthcare infrastructure, and growing medical tourism industry in developing nations such as China, and India in this region. Among all the types, deep vein thrombosis (DVT) has the highest market share in the venous thromboembolism treatment market.

This report identifies the venous thromboembolism treatment market size for the years 2014-2016, and forecast of the same till the year 2022. It also highlights the market drivers, restraints, growth indicators, challenges, and other key aspects with respect to the venous thromboembolism treatment market.

This report segments the venous thromboembolism treatment market on the basis of type, treatment, and regional market as follows:

Venous Thromboembolism Treatment Market, By Type: Deep Venous Thrombosis, and Pulmonary Embolism
The report has focused study on venous thromboembolism treatment market by basis of treatment such as: Heparin, Apixaban, Dabigatran, Rivaroxaban, Edaxaban, Warfarin, Compression Therapy, Inferior Vena Cava Filter, and Thrombolytic Therapy
This report has been further segmented into major regions, which includes detailed analysis of each region such as: North America, Europe, Asia-Pacific (APAC), and Rest of the World (RoW) covering all the major country level markets in each of the region

This report identifies all the major companies operating in the venous thromboembolism treatment market. Some of the major companies’ profiles in detail are as follows:

Abbott Laboratories
Bio Compression Systems, Inc.

Boehringer Ingelheim GmbH
Upsher-Smith Laboratories,Inc
Bristol-Myers Squibb Company
Please Note: The report is to be delivered in 1-2 working days after an order is placed.
Note: Product cover images may vary from those shown
2 of 2
1. Venous Thromboembolism Treatment Market – Overview

2. Executive Summary

3. Venous Thromboembolism Treatment Market Landscape
3.1. Market Share Analysis
3.2. Comparative Analysis
3.3. Product Benchmarking
3.4. End User Profiling
3.5. Top 5 Financials Analysis

4. Venous Thromboembolism Treatment Market– Forces
4.1. Drivers
4.1.1. Development of efficient and advance technology
4.1.2. Growing prevalence and incidence rate of venous thromboembolism
4.2. Restraints
4.2.1. Higher cost of research and development
4.3. Opportunities
4.3.1. Emerging economies
4.4. Challenges
4.5. Porter’s Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Degree of Competition

5. Venous Thromboembolism Treatment Market– Strategic Analysis
5.1. Value Chain Analysis
5.2. Pricing Analysis
5.3. Opportunities Analysis
5.4. Product/Market Life Cycle Analysis
5.5. Suppliers and Distributors

6. Venous Thromboembolism Treatment Market, By Type
6.1. Deep Venous Thrombosis
6.2. Pulmonary Embolism

7. Venous Thromboembolism Treatment Market, By Treatment
7.1. Heparin
7.2. Apixaban
7.3. Dabigatran
7.4. Rivaroxaban
7.5. Edaxaban
7.6. Warfarin
7.7. Compression Therapy
7.8. Inferior Vena Cava Filter
7.9. Thrombolytic Therapy

8. Venous Thromboembolism Treatment Market, By Geography
8.1. Europe
8.1.1. Germany
8.1.2. France
8.1.3. Italy
8.1.4. Spain
8.1.5. Russia
8.1.6. U.K.
8.1.7. Rest of Europe
8.2. Asia Pacific
8.2.1. China
8.2.2. India
8.2.3. Japan
8.2.4. South Korea
8.2.5. Rest of Asia-Pacific
8.3. North America
8.3.1. U.S.
8.3.2. Canada
8.3.3. Mexico
8.4. Rest of the World (RoW)
8.4.1. Brazil
8.4.2. Rest of RoW

9. Venous Thromboembolism Treatment – Entropy
9.1. Expansion
9.2. Technological Developments
9.3. Merger & Acquisitions, and Joint Ventures
9.4. Supply- Contract

10. Company Profiles (Overview, Financials, SWOT Analysis, Developments, Product Portfolio)
10.1. Abbott Laboratories
10.2. Bio Compression Systems, Inc.
10.3. Boehringer Ingelheim GmbH
10.4. Upsher-Smith Laboratories,Inc
10.5. Bristol-Myers Squibb Company
10.6. Merck & Co.
10.7. Dupont Pharm Co
10.8. Wockhardt Ltd
10.9. Bayer AG
10.10. Pfizer Inc.
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"

11. Appendix
11.1. Abbreviations
11.2. Sources
11.3. Research Methodology
11.4. Bibliography
11.5. Compilation of Expert Insights
11.6. Disclaimer
Note: Product cover images may vary from those shown
3 of 2